CHICAGO – For those already cowed by the genetic diversity of cancer, Charles Swanton, of the Institute for Cancer Research/Royal Marsden Hospital, had some depressing news at the American Society for Clinical Oncology's (ASCO) annual meeting. Read More
Analysts, inspecting early stage data, hailed the "paradigm-changing" potential in the treatment of at least one set of non-small-cell lung cancer (NSCLC) patients with Clovis Oncology Inc.'s oral CO-1686, for which results from Phase I/II trials were reported at ASCO 2013. Read More
Much-awaited data from Synta Pharmaceuticals Corp.'s mid-stage GALAXY-1 study left investors less than satisfied, as shares of the Lexington, Mass.-based biotech dropped 34 percent. Read More
Amgen Inc. didn't exactly take the blue ribbon for data on oncolytic immunotherapy talimogene laherparepvec, better known as T-VEC, at ASCO 2013. However, a first pass at key overall survival (OS) findings suggested the compound may still be in the mix for melanoma, though perhaps with a lower anticipated market opportunity than currently marketed Yervoy (ipilimumab, Bristol-Myers Squibb Co.) and highly anticipated PD-1 therapies. Read More
CHICAGO – From a scientific perspective, at least, the RTOG 0825 and AVAglio studies were a terrific success: they suggested plenty of avenues for future research. Read More
Some advisory committee members may think they're listening to a broken record when they convene for the third time in seven years Wednesday to once again discuss the cardiovascular (CV) risk of GlaxoSmithKline plc's (GSK) diabetes drug Avandia and its open-label, noninferiority RECORD trial. Read More
LONDON – Bergenbio AS has raised $6 million in a Series B round supported by all the existing investors, providing funding for a number of Phase I trials of its lead product BGB 324, a first-in-class AXL receptor tyrosine kinase inhibitor. Read More
• Inflection Biosciences Ltd., of Dublin, Ireland, said it entered a license agreement with the Spanish National Cancer Research Centre (CNIO) for exclusive, worldwide rights to develop and commercialize several kinase inhibitors for the treatment of cancer. Read More
• CorMedix Inc., of Bridgewater, N.J., received a notice from the New York Stock Exchange that CorMedix made reasonable demonstration of its ability to regain compliance with the exchange's rules, and CorMedix's listing will continue through Oct. 20. Read More
• Renaissance Acquisition Holdings LLC, of Montreal, and GlaxoSmithKline plc, of London, entered an agreement giving Renaissance the rights in the U.S. to manufacture, market and sell six dermatology and three antiviral products from GSK. Read More
• Keryx Biopharmaceuticals Inc., of New York, presented updated efficacy and safety data from the Phase III long-term trial of Zerenex (ferric citrate), the company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. Read More
